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Background: Pulmonary arterial hypertension (PAH) is a disorder in which pulmonary arterial remodeling and vasoconstriction lead to exercise 
intolerance, right heart failure (RHF) and death. Beta-blockers (BB) improve ventricular function and reduce mortality in left heart failure but their 
risks and benefits in PAH remain uncertain.
Methods: This is a prospective cohort study of 54 PAH patients comparing outcomes between those on BB (BB+, n=15) or not (BB-, n=39) at 
baseline (BL). Rates of all cause mortality, PAH-related hospitalization, six minute walk test (6MWT), right ventricular function determined by 
echocardiography and hemodynamics measured by right heart catheterization were compared.
Results: Overall BB use in this PAH cohort was common (28%). After a median follow-up of 14 months, there were no differences in PAH-related 
hospitalization or all cause mortality (p=0.27) and RHF at last visit (p=0.86). All BL and last echocardiographic and hemodynamic parameters were 
similar, except that BB+ had lower BL heart rate (p=0.01), higher BL right atrial pressure (p=0.002) and a higher percentage of moderate to severe 
tricuspid regurgitation at last visit (p=0.01). 6MWT was lower in BB+ at BL (p=0.046) but not at last visit (p=0.07, figure).
Conclusions: This prospective cohort study demonstrates that BB use is common in PAH patients and is tolerated in terms of clinical and 
functional parameters and mortality. Future large, randomized-controlled studies are warranted. 
